Tal vez has escuchado muchos medicamentos para el tratamiento de la enfermedad por Coronavirus, ¿pero realmente sabes cómo funcionan? o ¿realmente sabes si funcionan?. No te pierdas este vídeo donde veremos las más importantes hasta ahora y los avances en su investigación.
EDICIÓN Y GRABACIÓN POR
– JC Brothers Inc
*********************************
SUSCRÍBETE: www.youtube.com/c/JuanCanoMD
**********************************
REFERENCIAS
– Cloroquina e Hidroxicloroquina
1. Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30:269-271.
2. Keyaerts E, Vijgen L, Maes P et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004; 323:264-8.
3. Cortegiani A, Ingoglia G, Ippolito M et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020.
4. Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agnts. 2020
5. US Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): Information for Clinicians on Therapeutic Options for COVID-19 Patients. From CDC website.
6. CDC. Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19). From CDC website (
– Remdesivir
1. Agostini ML, Andres EL, Sims AC et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018; 9.
2. Brown AJ, Won JJ, Graham RL et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019; 169:104541.
3. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020
ESTUDIOS CLÍNICOS FASE III
1. NCT04292899 – Study to evaluate the safety and antiviral activity of remdesivir (GS-5734) in participants with severe coronavirus disease (COVID-19). NCT04292899. (
NCT04292899)
2. NCT04292730 – Study to evaluate the safety and antiviral activity of remdesivir (GS-5734) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment. NCT04292730. (
– Lopinavir/Ritonavir
1. Chu CM, Cheng VC, Hung IF et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004
2. Cao B, Wang Y, Wen D et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020
3. Yao TT, Qian JD, Zhu WY et al. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020
– Oseltamivir
1. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020
2. Tan EL, Ooi EE, Lin CY et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004
– Tocilizumab
1. Xu X, Han M, Li T et al. Effective treatment of severe COVID-19 patients with Tocilizumab. Available on chinaXiv website. Accessed online 2020 Mar 19
2. Mehta P, McAuley DF, Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 16: pii: S0140- 6736(20)30628-0 [Epub ahead of print].
ESTUDIOS CLÍNICOS FASE III
1. NCT04317092 – U.S. National Library of Medicine. ClinicalTrials.gov. Accessed 2020 Apr 1. Available from NLM identifier: NCT04317092.
2. NCT04320615 – U.S. National Library of Medicine. ClinicalTrials.gov. Accessed 2020 Apr 2. Available from NLM identifier: NCT04320615
– Azitromicina
1. Molina JM, Delaugerre C, Goff JL, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID19 infection. Médecine et Maladies Infectieuses. 2020. Preprint.
2. Giudicessi JR, Noseworthy PA, Friedman PA et al. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID19. Mayo Clin Proc. Preprint. DOI: 10.1016/j.mayocp.2020.03.024
source
